Teethgrinder – Lifestyle
Author:
Apogee Therapeutics
Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results
May 11, 2026
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
March 24, 2026
Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering
March 23, 2026
Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis
March 23, 2026
Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026
March 22, 2026